treatment

Rodrigo Calado, MD, PhD

Institution
Hospital das Clínicas de Ribeirão Preto
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Graduated in Medicine (1997) and PhD in Clinical Medicine (2003) from the Ribeirão Preto Medical School of the University of São Paulo (FMRP-USP) and medical residency in Hematology and Hemotherapy (2001) from the Hospital das Clinicas of FMRP-USP. He did postdoctoral studies at the National Institutes of Health, Bethesda, Maryland, USA, where he also worked as a Staff Scientist at the Hematology Branch until 2011. He is currently an Associate Professor in the Department of Clinical Medicine at FMRP-USP, coordinator of the Hematology and Program discipline Graduate Program in Oncology, Stem

Salman Fazal, MD

Institution
West Penn Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)

Melhem Solh, MD

Institution
Northside Hospital Cancer Institute
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Melhem Solh, M.D., is board certified in the subspecialties of medical oncology and hematology. Dr. Solh is a Northside Hospital Blood and Marrow Transplant and Leukemia Program physician.In 2019, Dr. Solh was recognized as among Atlanta’s Top Doctors in his specialty by Castle Connolly.

Michael Burke, MD

Institution
Children's Wisconsin-Milwaukee Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Pediatric
About
Dr. Michael Burke is an Associate Professor at the Children’s Hospital of Wisconsin (CHW) in the Division of Hematology/Oncology/Blood & Marrow Transplantation. He is Director of the Pediatric Leukemia & Lymphoma Program at CHW and Co-Director of the Developmental Therapeutics Program where he oversees all early phase clinical trials (Phase I and II studies) at CHW. He has developed both early phase and upfront clinical trials in acute leukemia that have opened locally here at CHW as well as nationally and internationally through consortiums such as the Children’s Oncology Group (COG) and the

AML Research Efforts in Full Swing After Decades of Stagnation

Original Publication Date
Article Source
External Web Content
After decades of few advances and stagnant treatment approaches, which mainly comprised 7+3 chemotherapy, the acute myeloid leukemia (AML) paradigm now has several agents approved, and plenty of ongoing trials are exploring other novel therapies alone and in combination…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.